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Abstract 
Objective: 
To determine the percentage of laboratories in the United States that have adopted the 
World Health Organization 2010 (WHO 5) semen analysis (SA) reference values six years after 
their publication.  
 
Methods: 
Laboratories were identified via three approaches: using the Clinical Laboratory 
Improvement Amendments (CLIA) website, the CDC’s 2015 Assisted Reproductive Technology 
Fertility Clinical Success Rate Report, and automated web searches. Laboratories were 
contacted by phone or email to obtain de-identified SA reports and reference ranges. 
 
Results:  
We contacted 617 laboratories in 46 states, of which 208 (26.7%) laboratories in 45 
states were included in our analysis. 132 (63.5%) laboratories used WHO 5 criteria, 57 (27.4%) 
used WHO 4 criteria, and 19 (9.1%) used other criteria. WHO 5 criteria adoption rates varied by 
geographic region, ranging from 87.5% (35/40) in the Midwest to 50.0% (33/66) in the West. 
There was a greater adoption rate of WHO 5 reference values in academic affiliated (23/26, 
88.5%) compared to non-academic affiliated laboratories (110/182, 60.4%) (P=0.028). 
 
Conclusion: 
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While the majority of laboratories have adopted WHO 5 criteria following its release six 
years ago, a large percentage (36.5%) use what is now considered outdated criteria. This 
variability could result in the characterization of a male’s semen values as being “within 
reference range” at one center and “outside of reference range” at another. This inconsistency 
in classification may result in confusion for the both patient and physician and potentially shift 
the burden of infertility evaluation and treatment to the female partner.  
 
 
 
INTRODUCTION 
Approximately 15% of couples experience difficulty conceiving; male factor infertility 
problems have been found to be solely responsible in 20%, and contributory along with female 
factors in another 30 – 40% of cases[1]. Semen analysis (SA) is typically the first step in 
evaluating the male partner in couples seeking infertility treatment. Abnormalities in the SA 
prompt further workup for male factor infertility problems, while a normal SA often results in 
pursuing possible female factor infertility problems[2-6].  
There is currently no set of reference ranges for SA which has been universally adopted. 
Among other causes, this lack of standardization leads to variable inter- and intra-laboratory 
reliability [7-10]. Many laboratories use the World Health Organization (WHO) reference ranges, 
which provide reference value recommendations for semen volume, sperm concentration, 
sperm motility, and % normal sperm morphology. The adoption rates of the previous 1999 
edition (WHO 4) criteria were found to be as low as 23% according to a study published 10 
years after its release[11]. 
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The WHO 5 reference values were developed by Cooper et al. by analyzing SA results 
from a large sample of men with proven fertility[12, 13]. The data was acquired from multiple 
centers across diverse populations to identify reference intervals for values of semen 
parameters which can be extrapolated to the general population of fertile men. The reference 
values reflect the lower fifth centile (with 95% confidence intervals) of the study cohort. Since its 
publication in 2010, many publications have critiqued the changes applied to the WHO 4 
criteria[14-18]. 
It is unknown how many laboratories utilize the WHO 5 reference values, now eight 
years after their release. We hypothesize that a substantial percentage of laboratories 
performing SA in the United States have not adopted WHO 5 criteria. This study attempts to 
determine the percentage of laboratories that have adopted the WHO 5 criteria based on a 
sampling of laboratories performing SA in the United States. 
 
MATERIALS AND METHODS 
A three-prong methodology was developed to identify laboratories. First, Clinical 
Laboratory Improvement Amendments (CLIA) laboratories were identified for query through the 
CLIA website (https://wwwn.cdc.gov/clia/Resources/LabSearch.aspx) using a search of the 
laboratory name with the terms: “andrology,” “infertility,” “semen analysis,” or “reproductive” to 
identify laboratories that perform SA in the United States. Information extracted included the 
laboratory name, accreditation, street address, email address, and phone number. Second, 
each of the labs listed in the CDC’s 2015 Assisted Reproductive Technology Fertility Clinical 
Success Rates Report were considered and duplicates identified through method one were 
excluded. Finally, automated web searches were conducted to gather a list of one hundred 
candidate websites per search, using query phrases including “semen analysis,” “seminogram,” 
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“andrology,” “infertility,” “sperm count,” “sperm motility,” and “sperm morphology.” The complete 
text was retrieved from each website and parsed for entity extraction using a natural language 
API. From the extracted text data, potential names of SA laboratories were identified from the 
list of phrases linked to the “organization” entity type using an algorithm analyzing whether the 
surrounding text addressed the topic of SA. Laboratories were cross-referenced with those 
gathered from methods one and two, and duplicates were excluded. Laboratories were 
contacted first by email, and then by phone if they did not respond or did not have an email 
listed. De-identified SA reports or reference ranges from responding laboratories were then 
obtained. Laboratories were excluded from the study if they did not perform SA, did not respond 
to our inquiry, the phone number was incorrect, or if the phone number was a duplicate. Each 
laboratory was counted only once in the analysis, regardless of the number of fertility centers it 
served. Laboratory affiliation with an academic center was determined based on an internet 
search with the laboratory’s name and address. 
The rate of WHO criteria adoption was computed by comparing reference range values 
and SA reports to WHO criteria (Table 1). Laboratories were also stratified by geographic region 
(West, Midwest, South, and Northeast) of the United States. Statistical analysis was performed 
using SPSS software (Version 21, IBM Corporation, Armonk, N.Y.). A chi-square test was used 
to compare the rate of WHO 5 criteria adoption between academic affiliated and non-academic 
affiliated laboratories. Significance was set at a p value of < 0.05. 
 
RESULTS 
Our search resulted in 697 laboratories in 46 states. Four hundred eighty nine (70.2%) 
laboratories were excluded from the analysis: 319 (65.2%) did not reply to our inquiry, 36 (7.4%) 
were wrong numbers, 80 (16.4%) were duplicate laboratories or fertility centers using a 
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laboratory that had already been contacted in our study, and 54 (7.7%) did not perform SA. We 
obtained SA reference ranges from 208 (29.8%) laboratories in 45 states. Our search resulted 
in 64 (9.2%) academic affiliated laboratories and 633 (90.8%) non-academic affiliated 
laboratories, of which we obtained reference values from 26 (40.6%) and 182 (28.8%) 
laboratories, respectively. 
 Our results included reference values from 66 (31.7%) laboratories located in the West 
(MT, NM, AZ, CA, CO, HI, ID, NV, OR, UT, WA), 40 (19.2%) in the Midwest (NE, SD, WI, IL, IN, 
KS, MI, MN, MO, OH), 65 (31.7%) in the South (OK, LA, AL, AR, DC, DE, FL, GA, KY, MD, MS, 
SC, TN, TX, VA), and 37 (17.8%) in the Northeast (NC, WV, CT, MA, NH, NJ, NY, PA, RI). 
WHO 5 criteria were utilized by 132 (63.5%) laboratories, while 57 (27.4%) used WHO 4 
criteria. 19 (9.1%) laboratories did not comply with either WHO 4 or WHO 5 criteria; their 
reference values included WHO 3 criteria (n=6) or modified WHO criteria (n=11) (Table 2). 2 
labs (1%) stated they used parameters other than the WHO 4 or WHO 5, but would not specify 
the reference values used (Table 2). WHO 5 adoption rates varied greatly by geographic region, 
with 87.5% (35/40) in the Midwest, 61.5% (24/39) in the Northeast, 60.3% (38/63) in the South, 
and 50.0% (33/66) in the West (Figure 1). WHO 5 criteria adoption differed among academic 
centers (23/26, 88.5%) compared to non-academic centers (110/182, 60.4%) (p=0.028). 
 
DISCUSSION 
Semen analysis remains an essential step in diagnosing a male factor infertility problem. 
The S  results help guide the workup and treatment of a couple experiencing infertility. The 
AUA Best Practice Statement[6] entitled, “Optimal Evaluation of the Infertile Male,” recommends 
a full evaluation of the male in the setting of two abnormal screening SA, while a normal SA will 
often result in the burden of the workup falling to the female. Laboratories performing SA are 
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held to federal CLIA regulations, but are not required to conform to any specific criteria for their 
reference values[19]. The WHO 5 reference values are recommendations based on empiric 
evidence from data pooled from multiple studies across different populations. The WHO 5 
recommendations recognize that there may be variations in normal semen analysis parameters 
by region, as was found by Jorgensen et al.,[20] and recommend that laboratories should 
consider preparing their own reference ranges to account for the regional variation. However, 
there is currently not enough data to accurately define individual reference ranges by region[12]. 
In the absence of specific regional data, most laboratories utilize the reference ranges 
published by the WHO, but many do not adopt the most up to date recommendations. In 2010, 
Penn et al.[11] found that only 23% of laboratories that they surveyed in the United States had 
adopted the recommended WHO 4 criteria 10 years after its publication. There are many 
different components of inter- and intra-laboratory standardization for SA, and the reference 
values are only one part of the process. Other problems that have been noted in the literature 
include lack of standardization in specimen preparation, variation in the technique used to 
evaluate the specimen, and lack of internal and external quality control measures[7-10, 21]. In 
2005, Riddell et al.[22] reported that only 5% of the laboratories surveyed in the United Kingdom 
used the techniques set out in the WHO 4 recommendations for assessing sperm morphology. 
The inconsistency across laboratories in the various domains highlights the problem addressed 
in this study: a lack of standardization amongst laboratories leads to variable categorizations of 
men as within the reference ranges in one laboratory and outside the reference ranges in 
another. 
The main criticism of the WHO 5 reference values is that they were developed from the 
SA of fertile men only. The implications of this are twofold: approximately 5% of fertile men will 
be outside the reference ranges, and a man with SA values within the reference ranges, but no 
pregnancy for over one year, is still subfertile. The SA measures concentration, motility, and 
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appearance of sperm, which are used as surrogate screening tests for fertility, but does not 
measure fertility directly. Despite criticisms however, the WHO 5 criteria are lauded for providing 
the first evidence-based reference ranges for SA parameters and for providing techniques to 
help standardize laboratory results[23, 24].  
 The WHO 5 reference values decreased the lower limit of the reference ranges, 
resulting in classification of some men as within the reference ranges who would otherwise have 
been outside the reference ranges under the WHO 4 criteria[23, 25, 26]. Murray et al.[15] found 
that 103 of 501 (15%) patients on retrospective analysis would have had one or more parameter 
outside the reference range according to WHO 4 criteria while having all the parameters within 
the reference ranges with WHO 5 criteria. It may be argued that the lower reference values in 
WHO 5 reflect a gradual decline in the fecundity which has been described over the past 3 
decades[27], however the overall decline in semen parameters has been widely disputed, and 
high quality data to confirm this hypothesis is lacking[28, 29]. 
In collecting data from 208 laboratories, this study is the largest of its kind. These data 
confirm our hypothesis: just over one-third (36.5%) of the surveyed laboratories did not adopt 
the WHO 5 reference ranges. Interestingly, this is a substantially lower percentage than 
previous reports of WHO 4 criteria adoption in 2010[11]. This difference could, in part, be 
explained by the fact that these reference ranges are “evidence-based” and thus might be 
considered by some to be more clinically relevant than previous criteria. It is also possible that 
there was not a large change from the 1992 (WHO 3) criteria[30] to the WHO 4 criteria. 
Therefore, laboratories may have felt less inclined to adopt WHO 4 reference ranges than when 
presented with a larger change in the reference values as seen with WHO 5 criteria[11]. While it 
is conceivable that greater standardization in the reference values might be a step towards 
higher reliability amongst laboratories, the fact that the WHO 5 reference ranges were 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 9 
generated without the consideration of any data from infertile male patients remains a 
substantial limitation and point of contention among many experts.  
We also found a discrepancy in rates of WHO 5 criteria adoption in geographic regions 
across the country, ranging from 87.5% adoption in the Midwest to only 50% adoption in the 
West. Awareness of geographical differences is important for clinical practice as these results 
suggest that patients are more likely to have their SA performed at a laboratory using the WHO 
5 reference values if they are in the Midwest or the Northeast than if they are in the West or the 
South. Additionally, a larger percentage of academic affiliated laboratories were found to have 
adopted the WHO 5 criteria, which reached statistical significance when compared to non-
academic affiliated laboratories. However, the disproportionate number of academic and non-
academic affiliated laboratories must be considered when interpreting this finding. 
The findings of this study are important to consider as a lack of standardized reference 
values can result in a patient being considered within the reference ranges in one laboratory, 
and outside the reference ranges in another laboratory, even in the same geographic region. 
This inconsistency can lead to anxiety and confusion for both the patient and clinician. The 
confusion can impact the management of the patient and his partner depending when or where 
they seek treatment and is especially crucial with a time-sensitive issue, such as infertility. This 
is vital for providers to take into account when interpreting SA results and counseling their 
patients on the next steps of the couple’s infertility workup. 
The limitations of this study need to be considered when interpreting the results. 
Laboratories were given the option to provide a sample SA, or to provide the reference values 
that they use. In a few cases, laboratories reported that they use WHO 5 criteria, while the 
reference values they provided were actually in concordance with the WHO 4 criteria. These 
laboratories were categorized appropriately in our study as utilizing WHO 4 criteria, but it is 
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important for physicians to note that when queried on their reference ranges, there may be a 
discrepancy between the reported criteria being followed and the actual reference values being 
used.  
The search of the CLIA website was conducted based on a search of laboratory names, 
which resulted in laboratories without these terms in their name being excluded from our study. 
Though an attempt to mitigate unnecessary exclusion by utilizing the 2015 Assisted 
Reproductive Technology Fertility Clinical Success Rates Report and by developing a natural 
language API, a risk of exclusion persists. This, as well as our sample size of n=208 could 
introduce bias into our results. The lower percentage of academic affiliated laboratories 
surveyed could result in under- or over-representing the WHO 5 adoption rates among 
academic compared to non-academic affiliated laboratories. A larger sample size could improve 
the generalizability of the data. However, the laboratories were selected randomly across 45 
states, with a close distribution among the geographical regions, which decreases the likelihood 
of sampling bias.  
An additional limitation is that this study only examined reference ranges, and did not 
address any of the other areas that can result in inter- and intra- laboratory variability, such as 
sample preparation, examination technique, and quality control measures. Morphology, in 
particular has been found to be a large contributor to intra-laboratory variability. Both the WHO 4 
and WHO 5 reference ranges are based on the recommended strict morphology criteria[31], 
however it is unclear how many laboratories are using this criteria, even if reporting the WHO 4 
or 5 reference ranges [8, 9]. These issues are addressed in the WHO 5 recommendations, and 
measuring compliance with these metrics is an important area of future study. 
With so many laboratories performing SA, it may prove difficult to achieve 
standardization across laboratories. However, given how crucial the SA is for the infertility 
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workup of the couple, achieving SA reliability among laboratories should be a priority. Also, 
given the variability in SA among fertile men, large regional studies are needed to more 
accurately characterize reference ranges and appropriate treatment thresholds in order to avoid 
undue placement of the burden for diagnosis and care on the female partner.  
 
CONCLUSION 
While the majority of laboratories in the United States have adopted WHO 5 reference 
range criteria, a large percentage (36.5%) still use other criteria six years after the WHO 5 
criteria were published. This variability could result in a male patient being characterized as 
"fertile" in one center and "subfertile" in another, leading to inconsistencies in treatment, and 
potentially shifting the burden of the infertility workup and interventions to the female. This 
discrepancy is particularly relevant given that, contrary to earlier standards, the WHO 5 criteria 
were developed from a population of normal, fertile males and did not contain infertile males. 
The current lack of consensus amongst laboratories in SA reference ranges could thus 
substantially impact the management of the male patient and his partner, simply depending on 
where they seek treatment. While large regional studies are needed to develop region-specific 
reference ranges, more consistent adoption of existing reference values would help to 
standardize the categorization of males and the subsequent approach to couples experiencing 
infertility. 
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FIGURE 1: Semen Analysis Parameter Reference Values by US Region.  
Adoption rates of WHO 5, WHO 4, or other reference ranges stratified by region of the United 
States. 
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TABLE 1: WHO Semen Analysis Reference Ranges 
 
 
TABLE 2: Semen Analysis Reference Ranges Utilized by Laboratory 
Semen Analysis Reference Ranges Utilized by Laboratory Number (%) of 
Laboratories 
WHO 5 criteria 132 (63.5%) 
WHO 4 criteria 57 (27.4%) 
Other 19 (9.1%) 
WHO 3 criteria 6 (2.9%) 
WHO 4 volume and concentration, WHO 5 
morphology, progressive motility 40% 
4 (1.9%) 
WHO 5 volume and concentration, WHO 4 
morphology, progressive motility 40% 
5 (2.4%) 
WHO 4 volume and WHO 5 morphology 1 (0.5%) 
WHO 5 concentration and morphology, WHO 4 
volume, progressive motility 40% 
1 (0.5%) 
Other criteria, unspecified 2 (1.0%) 
 
 
Semen Parameter WHO 3 (1992) WHO 4 (1999) WHO 5 (2010) 
Volume (mL) 2.0 2.0 1.5 (1.4–1.7) 
Total sperm number (106) 40 40 39 (33-46) 
Semen Concentration (106/mL) 20 20 15 (12-16) 
Progressive motility (% progressive) 50 50 32 (31-34) 
Normal morphology (%) 30 15 4 (3.0-4.0) 
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 The inconsistent adoption of the WHO 5th edition (2010) semen analysis reporting 
standard by laboratories is a huge problem in clinical andrology.  Although the study by [First 
author last name] and colleagues has a few methodological shortcomings, its simple design is 
particularly effective at conveying the magnitude of this widespread problem.  For those in a 
reproductive medicine specialty practice it will not be surprising, but for the rest of the urology 
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community it will be staggering to see that over a third of U.S. laboratories are performing 
semen analyses according to decades-old standards1. 
While the WHO 5th edition standard is not perfect, it is the best and most current 
standard adopted by laboratories and reproductive centers worldwide to characterize a semen 
analysis on the spectrum of normal fertility.  To that point, it is important to understand that 
these “reference ranges” do not represent fertile (normal) versus infertile (abnormal) in the same 
way that a white blood cell count can either be normal or represent an abnormal leukocytosis.  
Rather, the lower limit of normal for each parameter is in fact the 5th percentile of men with 
normal fertility, therefore indicating where on the continuum of normal fertility a particular semen 
parameter may be.  Unfortunately, while a complete blood count result from another laboratory 
can easily and reliably be interpreted by a clinician, we cannot always say the same about a 
semen analysis.  There are multiple reasons for this, with one of the primary reasons being 
inconsistent laboratory reporting. 
Prior to the most recently published reference range in the WHO 5th edition (2010), the 
second most recent edition (1999) is now approaching 20 years old.  It is not invalid to report a 
result alongside an outdated reference range; however, when labs do not follow the most 
current standard of reporting, it represents a “red flag” to the clinician that the lab may not only 
perform semen analyses infrequently, but also, more importantly, may be out of touch with 
modern andrology assessment techniques.  The resulting drawback is particularly evident with 
sperm morphology, which went through a significant change when Kruger strict morphology was 
adopted for the 5th edition.  The light microscopy version of morphology assessment, which was 
part of the 1999 and earlier WHO reference standards, is now obsolete and relatively useless to 
clinicians.  Nevertheless, this change in morphology reporting is likely a factor in why some 
laboratories have not adopted the most current standard.   
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Not only are non-conforming labs out of touch and potentially less accurate, but results 
reported by such labs can lead to mischaracterizations of patients’ reproductive potentials, 
missed diagnoses, and ultimately can heighten the barriers to male reproductive care.  It is 
about time that CLIA-certified laboratories be required to conform to modern reference values in 
reporting semen analyses in order to maintain compliance.   
 
References: 
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We appreciate the reviewer’s comments regarding our manuscript. The inconsistent  adoption of WHO 
V (2010) semen analysis reference ranges can result in numerous unintended consequences, including 
inconsistencies in the diagnosis and treatment of male factor infertility depending simply on the location 
of the patient’s evaluation. Patients commonly express confusion and dismay when being categorized as 
“normal” at one center and “infertile” at another, and this scenario can also result in uncertainty on the 
part of physicians unfamiliar with the field of reproductive medicine. We agree with the reviewer that 
more consistent adoption of contemporary WHO semen analysis reference ranges would greatly help 
rectify this situation and provide patients and clinicians alike with great clarity. However, we suspect 
that a primary reason for the inconsistent adoption of the WHO V reference ranges is the fact that these 
values do not represent a true boundary between the “fertile” and “infertile” states. Rather, these 
values are arbitrary cut-points selected at the 5th centile value for each parameter, derived from data 
from an international cohort of fertile males. Given the fact that the contemporary refence values are 
not derived to differentiate fertile from infertile men, many centers continue to use the older reference 
ranges because they feel that they do a better job discriminating fertility from infertility.  Until reference 
ranges that more clearly separate these two groups are implemented, inconsistent adoption will likely 
persist. Unfortunately, given the high degree of overlap in semen analysis values for fertile and infertile 
men, we suspect that such reference ranges will not be generated any time soon.  
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